Advancing the treatment of hematologic malignancies through the development of targeted interventions
- 1 October 2002
- journal article
- review article
- Published by Elsevier in Seminars in Hematology
- Vol. 39 (4) , 1-5
- https://doi.org/10.1053/shem.2002.36919
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1HBlood, 2001
- Common themes in the pathogenesis of acute myeloid leukemiaOncogene, 2001
- Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell LeukemiaNew England Journal of Medicine, 2001
- Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First RelapseJournal of Clinical Oncology, 2001
- Fatal myeloproliferation, induced in mice by TEL/PDGFβR expression, depends on PDGFβR tyrosines 579/581Journal of Clinical Investigation, 2000
- Immunotoxins in cancer therapyCurrent Opinion in Immunology, 1999
- The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemiaNature Genetics, 1999
- Transforming Properties of the Huntingtin Interacting Protein 1/ Platelet-derived Growth Factor β Receptor Fusion ProteinJournal of Biological Chemistry, 1999
- Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.Journal of Clinical Oncology, 1997
- Humanized CD52 monoclonal antibody campath‐1H as first‐line treatment in chronic lymphocytic leukaemiaBritish Journal of Haematology, 1996